• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    NanoVibronix Signs Agreement For Research And Development Of Next Generation PainShield And UroShield

    3/28/24 8:36:02 AM ET
    $NAOV
    Industrial Specialties
    Health Care
    Get the next $NAOV alert in real time by email

    Efforts Focused on Adding Therapeutic Functionality and Reducing Costs

    NanoVibronix, Inc. (NASDAQ:NAOV) ("NanoVibronix" or the "Company"), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced it has entered into an agreement with Veranex, Inc. ("Veranex") to assist with the development of the company's next generation UroShield and PainShield products.

    Under the terms of the agreement, Veranex will provide certain research and development services as related to PainShield and UroShield.

    Brian Murphy, Chief Executive Officer of NanoVibronix, Inc., said, "Teaming up with Veranex provides us with access to additional industry expertise and manufacturing know-how to further improve our products and stay ahead of the innovation curve. By working with an outside partner with proven methods and techniques to evolve our products, we believe we will be able to offer a next generation of products that not only increases clinician and patient satisfaction but also future-proofs the components and reduces our cost of goods."

    Get the next $NAOV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NAOV

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NAOV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ENvue Medical, Formerly NanoVibronix, UroShield® Kit Secures Reimbursement in the UK

    TYLER, Texas, Dec. 18, 2025 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ:FEED) (NASDAQ:NAOV) ("ENvue," "ENvue Medical" or the "Company"), a medical technology company specializing in non-invasive therapeutic systems, today announced that the UroShield® Kit has been added to the UK National Health Service (NHS) Drug Tariff Part IX, enabling nationwide prescription reimbursement across the UK. In parallel with this reimbursement milestone, ENvue Medical has secured an initial purchase order from Peak Medical, a leading UK-based distributor specializing in stoma care and urology medical devices with a vast network of hospitals and community settings, reflecting early commercial demand fol

    12/18/25 12:30:35 PM ET
    $FEED
    $NAOV
    Industrial Specialties
    Health Care

    ENvue Medical's UroShield® Kit Secures Reimbursement in the UK

    TYLER, Texas, Dec. 18, 2025 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ:FEED) ("ENvue," "ENvue Medical" or the "Company"), a medical technology company specializing in non-invasive therapeutic systems, today announced that the UroShield® Kit has been added to the UK National Health Service (NHS) Drug Tariff Part IX, enabling nationwide prescription reimbursement across the UK. In parallel with this reimbursement milestone, ENvue Medical has secured an initial purchase order from Peak Medical, a leading UK-based distributor specializing in stoma care and urology medical devices with a vast network of hospitals and community settings, reflecting early commercial demand following NHS Dru

    12/18/25 9:00:00 AM ET
    $FEED
    $NAOV
    Industrial Specialties
    Health Care

    NanoVibronix, Inc. Announces Name and Ticker Symbol Change to ENvue Medical, Inc. and 'FEED'

    New ticker symbol, "FEED" will begin trading on the Nasdaq at the open of the market on December 12, 2025 NanoVibronix, Inc. (NASDAQ:NAOV) ("NanoVibronix" or the "Company"), a medical technology company specializing in non-invasive therapeutic systems, today announced that it will change its corporate name from NanoVibronix, Inc. to ENvue Medical, Inc., effective December 12, 2025, to better reflect its new strategic direction and primary focus on its ENvue® feeding-tube placement system ("ENvue"). The Company's ticker for its common stock, listed on the Nasdaq Capital Market, will also change to "FEED," which will begin trading under the new symbol beginning with the market open on the sa

    12/12/25 8:00:00 AM ET
    $NAOV
    Industrial Specialties
    Health Care

    $NAOV
    SEC Filings

    View All

    SEC Form 424B3 filed by NanoVibronix Inc.

    424B3 - ENvue Medical, Inc. (0001326706) (Filer)

    12/18/25 5:00:19 PM ET
    $NAOV
    Industrial Specialties
    Health Care

    NanoVibronix Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - NanoVibronix, Inc. (0001326706) (Filer)

    12/12/25 9:06:28 AM ET
    $NAOV
    Industrial Specialties
    Health Care

    Amendment: SEC Form S-3/A filed by NanoVibronix Inc.

    S-3/A - NanoVibronix, Inc. (0001326706) (Filer)

    12/9/25 9:28:07 PM ET
    $NAOV
    Industrial Specialties
    Health Care

    $NAOV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Pionati Pellegrino

    3 - ENvue Medical, Inc. (0001326706) (Issuer)

    12/18/25 5:40:32 PM ET
    $NAOV
    Industrial Specialties
    Health Care

    SEC Form 3 filed by new insider Johnson David Ian

    3 - ENvue Medical, Inc. (0001326706) (Issuer)

    12/18/25 5:36:25 PM ET
    $NAOV
    Industrial Specialties
    Health Care

    SEC Form 4 filed by Chief Executive Officer Murphy Brian M

    4 - NanoVibronix, Inc. (0001326706) (Issuer)

    1/3/25 4:05:16 PM ET
    $NAOV
    Industrial Specialties
    Health Care

    $NAOV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by NanoVibronix Inc.

    SC 13G/A - NanoVibronix, Inc. (0001326706) (Subject)

    11/14/24 5:17:34 PM ET
    $NAOV
    Industrial Specialties
    Health Care

    SEC Form SC 13G filed by NanoVibronix Inc.

    SC 13G - NanoVibronix, Inc. (0001326706) (Subject)

    2/14/24 3:45:41 PM ET
    $NAOV
    Industrial Specialties
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - NanoVibronix, Inc. (0001326706) (Subject)

    2/16/21 3:49:24 PM ET
    $NAOV
    Industrial Specialties
    Health Care

    $NAOV
    Financials

    Live finance-specific insights

    View All

    NanoVibronix Announces Distribution of Series F Preferred Stock to Holders of its Common Stock

    NanoVibronix, Inc. (NASDAQ:NAOV) ("Nano" or the "Company"), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series F Preferred Stock, par value $0.001 per share, for each outstanding share of the Company's common stock held of record as of 5:00 p.m. Eastern Time on October 14, 2022. The shares of Series F Preferred Stock will be distributed to such recipients at 5:00 p.m. Eastern Time on October 17, 2022. The outstanding shares of Series F Preferred Stock will vote together with the outstanding sh

    9/14/22 9:25:00 AM ET
    $NAOV
    Industrial Specialties
    Health Care

    $NAOV
    Leadership Updates

    Live Leadership Updates

    View All

    NanoVibronix Announces CEO Transition

    NanoVibronix, Inc. (NASDAQ:NAOV) ("NanoVibronix" or the "Company"), a medical technology company specializing in therapeutic devices, today announced the retirement of Brian Murphy as Chief Executive Officer, effective immediately. The Company's Board of Directors has appointed Doron Besser, CEO of ENvue Medical Holdings, LLC ("ENvue"), a wholly-owned subsidiary of the Company, as NanoVibronix's new CEO, also effective immediately. Mr. Murphy will remain on the Company's Board of Directors as a director. His continued service will support governance continuity at the Board level. As previously announced, on February 14, 2025, the Company consummated and completed its acquisition of ENvue,

    6/4/25 8:38:00 AM ET
    $NAOV
    Industrial Specialties
    Health Care

    NanoVibronix Announces Results of Annual Meeting of Stockholders Held Today

    NanoVibronix, Inc. (NASDAQ:NAOV) (the "Company"), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, announced that the Company's 2022 annual meeting of stockholders (the "Annual Meeting") was held today virtually and broadcast live at www.virtualshareholdermeeting.com/NAOV2022. The following resolutions submitted for stockholder approval were adopted: Election of the eight director nominees (Aurora Cassirer, Christopher Fashek, Michael Ferguson, Martin Goldstein, M.D., Harold Jacob, M.D., Thomas Mika, Brian Murphy, and Maria Schroeder) to serve on the Company's board of directors (the "Board"), for a term of on

    12/15/22 4:05:00 PM ET
    $NAOV
    Industrial Specialties
    Health Care

    NanoVibronix Reports First Quarter 2022 Financial Results

    Expanded Distribution, Entry into New Geographic Markets and Regulatory Approvals Advancing Efforts Towards Full Commercialization NanoVibronix, Inc., (NASDAQ:NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today reported its financial results for the quarter ended March 31, 2022. First Quarter 2022 Financial and Recent Business Highlights Revenue of $272,000, an increase of 164% compared to the prior year period Significant backlog of orders to be filled in Q2 Supply chain challenges are expected to abate moving into the second half of 2022 Submitted a 510(k) application to the U.S. Food and Dr

    5/17/22 8:30:00 AM ET
    $NAOV
    Industrial Specialties
    Health Care